title: Depression, selective serotonin reuptake inhibitors, and osteoporosis.
abstract: An increasing number of studies suggest an association between depression and osteoporosis. In a mouse model, depression induces bone loss, mediated by brain-to-bone sympathetic signaling. Depression and bone antianabolic sympathetic tone are alleviated by increasing central serotonin (5-hydroxytryptamine, 5-HT) levels. However, selective serotonin reuptake inhibitors (SSRIs), the first-line antidepressants, increase extracellular 5-HT levels but have deleterious skeletal effects. The skeletal serotonergic system consists of 5-HT receptors and the 5-HT transporter (5-HTT) in osteoblasts and osteocytes. 5-HTT is a transmembrane protein targeted by SSRIs. 5-HT restrains osteoblastic activity, thus leading to bone loss. Apparently, the negative skeletal effects of the peripheral SSRI-induced increase in 5-HT outweighs the skeletal benefits resulting from the enhanced central 5-HT antidepressant and antisympathetic activity. Overall, major depression appears as an important risk factor for osteoporosis. However, antidepressants, mainly SSRIs, should be evaluated in view of the causal relationship between depression and bone loss, and vis-à-vis their skeletal adverse effects. Patients with depressive disorders should undergo a routine skeletal evaluation and receive timely antiosteoporotic therapy, especially when SSRI treatment is prescribed.
authors.affiliation: The Hebrew University of Jerusalem, Israel. babi@cc.huji.ac.il
authors.forename: Itai
authors.initials: I
authors.lastname: Bab
authors.forename: Raz
authors.initials: R
authors.lastname: Yirmiya
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects; D015984:Causality; D015897:Comorbidity; D003863:Depression / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology; D006801:Humans; D010024:Osteoporosis / Q000453:epidemiology* / Q000503:physiopathology; D015663:Osteoporosis, Postmenopausal / Q000453:epidemiology / Q000503:physiopathology; D017698:Postmenopause / Q000502:physiology; D017697:Premenopause / Q000502:physiology; D011985:Receptors, Serotonin / Q000502:physiology; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D011985:Receptors, Serotonin; D017367:Selective Serotonin Reuptake Inhibitors
references.citation: Cell. 2009 Sep 4;138(5):976-89
references.pmid: 19737523
references.citation: Horm Metab Res. 2010 Jun;42(7):467-82
references.pmid: 20455194
references.citation: Nutr Rev. 2007 Dec;65(12 Pt 2):S147-51
references.pmid: 18240539
references.citation: Alcohol Res Health. 2001;25(4):276-81
references.pmid: 11910705
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):529-37
references.pmid: 11999904
references.citation: Lancet. 2001 Dec 15;358(9298):2061-8
references.pmid: 11755632
references.citation: J Clin Invest. 1998 Jul 15;102(2):274-82
references.pmid: 9664068
references.citation: Am J Epidemiol. 2006 Mar 1;163(5):421-32
references.pmid: 16394201
references.citation: Curr Top Med Chem. 2002 Jun;2(6):507-28
references.pmid: 12052191
references.citation: J Neurochem. 2008 Sep;106(6):2322-36
references.pmid: 18643796
references.citation: Thromb Res. 1999 Jul 1;95(1):1-18
references.pmid: 10403682
references.citation: Maturitas. 2007 Jan 20;56(1):1-11
references.pmid: 16806750
references.citation: Hormones (Athens). 2006 Jan-Mar;5(1):9-16
references.pmid: 16728381
references.citation: J Biol Chem. 2003 Oct 31;278(44):43146-56
references.pmid: 12939279
references.citation: Biol Psychiatry. 2009 Sep 1;66(5):423-32
references.pmid: 19446797
references.citation: Nature. 1951 Sep 1;168(4270):385
references.pmid: 14875097
references.citation: Curr Osteoporos Rep. 2006 Dec;4(4):134-9
references.pmid: 17112423
references.citation: Alcohol Clin Exp Res. 2005 Dec;29(12):2077-90
references.pmid: 16385177
references.citation: Mol Psychiatry. 2008 Jul;13(7):717-28
references.pmid: 17700577
references.citation: Arch Pediatr Adolesc Med. 2008 Dec;162(12):1181-8
references.pmid: 19047547
references.citation: Toxicol Appl Pharmacol. 2007 May 15;221(1):111-8
references.pmid: 17383703
references.citation: J Clin Endocrinol Metab. 2007 Feb;92(2):497-503
references.pmid: 17077132
references.citation: Mol Cell Endocrinol. 2005 Oct 20;242(1-2):1-9
references.pmid: 16085354
references.citation: J Pharmacol Exp Ther. 2008 Nov;327(2):316-23
references.pmid: 18708586
references.citation: Nat Med. 2010 Mar;16(3):308-12
references.pmid: 20139991
references.citation: J Cell Biochem. 2006 Apr 15;97(6):1283-91
references.pmid: 16329113
references.citation: Cell Metab. 2006 Nov;4(5):341-8
references.pmid: 17084709
references.citation: Bone. 2006 Dec;39(6):1313-21
references.pmid: 16884969
references.citation: J Clin Psychopharmacol. 2008 Aug;28(4):411-7
references.pmid: 18626268
references.citation: Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12956-61
references.pmid: 16126903
references.citation: Thorax. 1999 Feb;54(2):161-8
references.pmid: 10325923
references.citation: Cell. 2008 Nov 28;135(5):825-37
references.pmid: 19041748
references.citation: Curr Opin Pharmacol. 2007 Dec;7(6):648-52
references.pmid: 18032111
references.citation: Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16876-81
references.pmid: 17075068
references.citation: Inflamm Allergy Drug Targets. 2008 Mar;7(1):19-23
references.pmid: 18473896
references.citation: Addict Behav. 2006 Jan;31(1):133-6
references.pmid: 15922514
references.citation: FASEB J. 2008 Feb;22(2):418-27
references.pmid: 17846081
references.citation: Endocr Rev. 2002 Jun;23(3):279-302
references.pmid: 12050121
references.citation: Am J Physiol. 1994 Jan;266(1 Pt 1):L46-52
references.pmid: 8304469
references.citation: Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13960-5
references.pmid: 11717453
references.citation: J Neurosci. 1996 Apr 1;16(7):2352-64
references.pmid: 8601815
references.citation: FASEB J. 2008 Jan;22(1):285-94
references.pmid: 17704191
references.citation: Arch Biochem Biophys. 2008 May 15;473(2):231-6
references.pmid: 18410742
references.citation: Osteoporos Int. 2009 Aug;20(8):1309-20
references.pmid: 19343469
references.citation: Osteoporos Int. 2002 Dec;13(12):932-6
references.pmid: 12459935
references.citation: Pharmacol Ther. 2001 Nov-Dec;92(2-3):179-212
references.pmid: 11916537
references.citation: Lancet. 1997 May 24;349(9064):1498-504
references.pmid: 9167458